AIM: Chemerin is a novel adipokine that has been suggested to play an important role in the pathogenesis of the metabolic syndrome. The aim of our study was to evaluate serum chemerin as a marker of the metabolic syndrome and to assess its predictive accuracy in a Caucasian population. METHODS: The study was designed as a cross-sectional study. Anthropometric measurements and serum analyses were done for Body Mass Index, waist circumference, chemerin, insulin, triacylglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, uric acid, and glucose in 55 non-obese healthy subjects and 181 subjects at risk for the metabolic syndrome. ROC curves were determined and the Chi-squared test was used to analyse the data. RESULTS: Compared with healthy controls, subjects with suspected metabolic syndrome had significantly higher chemerin serum levels (medians: 266.0 vs.192.5 microg/l; P < 0.01). After further chemerin adjustment, the difference between the subgroups persisted. Chemerin serum levels correlated with age (r = 0.23), serum glucose (r = 0.23), HDL-cholesterol (r = -0.19), triacylglycerides (r = 0.22), systolic and diastolic blood pressure (r = 0.40; r = 0.24) and the number of metabolic syndrome risk factors (r = 0.47). At a serum chemerin cut-off level of 240 microg/l, the presence of the metabolic syndrome was diagnosed with 75 % sensitivity and 67 % specificity. CONCLUSION: In conclusion, serum chemerin levels are associated with the characteristics of the metabolic syndrome and could be an independent marker of this disorder in a Caucasian population.
AIM: Chemerin is a novel adipokine that has been suggested to play an important role in the pathogenesis of the metabolic syndrome. The aim of our study was to evaluate serum chemerin as a marker of the metabolic syndrome and to assess its predictive accuracy in a Caucasian population. METHODS: The study was designed as a cross-sectional study. Anthropometric measurements and serum analyses were done for Body Mass Index, waist circumference, chemerin, insulin, triacylglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, uric acid, and glucose in 55 non-obese healthy subjects and 181 subjects at risk for the metabolic syndrome. ROC curves were determined and the Chi-squared test was used to analyse the data. RESULTS: Compared with healthy controls, subjects with suspected metabolic syndrome had significantly higher chemerin serum levels (medians: 266.0 vs.192.5 microg/l; P < 0.01). After further chemerin adjustment, the difference between the subgroups persisted. Chemerin serum levels correlated with age (r = 0.23), serum glucose (r = 0.23), HDL-cholesterol (r = -0.19), triacylglycerides (r = 0.22), systolic and diastolic blood pressure (r = 0.40; r = 0.24) and the number of metabolic syndrome risk factors (r = 0.47). At a serum chemerin cut-off level of 240 microg/l, the presence of the metabolic syndrome was diagnosed with 75 % sensitivity and 67 % specificity. CONCLUSION: In conclusion, serum chemerin levels are associated with the characteristics of the metabolic syndrome and could be an independent marker of this disorder in a Caucasian population.
Authors: Gökhan Aksan; Sinan İnci; Gökay Nar; Korhan Soylu; Ömer Gedikli; Serkan Yüksel; Metin Özdemir; Rukiye Nar; Murat Meriç; Mahmut Şahin Journal: Int J Clin Exp Med Date: 2014-12-08
Authors: Shanmugam Muruganandan; Sebastian D Parlee; Jillian L Rourke; Matthew C Ernst; Kerry B Goralski; Christopher J Sinal Journal: J Biol Chem Date: 2011-05-14 Impact factor: 5.157
Authors: Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink Journal: FASEB J Date: 2018-06-15 Impact factor: 5.191
Authors: T Sledzinski; J Korczynska; A Hallmann; L Kaska; M Proczko-Markuszewska; T Stefaniak; M Sledzinski; J Swierczynski Journal: J Endocrinol Invest Date: 2012-11-27 Impact factor: 4.256